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Abstract  
Although fibrotic stroma forms an integral component of pancreatic diseases, whether fibroblasts 
programmed by different types of pancreatic diseases are phenotypically distinct remains unknown. 
Here we show that fibroblasts isolated from patients with pancreatic ductal adenocarcinoma (PDAC), 
chronic pancreatitis (CP), periampullary tumors (PAT), and adjacent normal (NA) tissue (N=34) have 
distinct mRNA and miRNA profiles. Compared to NA-fibroblasts, PDAC-associated fibroblasts were 
generally less sensitive to an anti-fibrotic stimulus (NPPB) and more responsive to positive regulators 
of activation such as TGFβ1 and WNT. Of the disease-associated fibroblasts examined, PDAC- and 
CP-derived fibroblasts shared greatest similarity, yet PDAC-associated fibroblasts expressed higher 
levels of Tenascin C (TNC), a finding attributable to miR-137, a novel regulator of TNC. TNC protein 
and transcript levels were higher in PDAC tissue versus CP tissue and were associated with greater 
levels of stromal activation, and conditioned media from TNC-depleted PDAC-associated fibroblasts 
modestly increased both PDAC cell proliferation and PDAC cell migration, indicating that stromal TNC 
may have inhibitory effects on PDAC cells. Finally, circulating TNC levels were higher in patients with 
PDAC compared to CP. Our characterization of pancreatic fibroblast programming as disease-specific 
has consequences for therapeutic targeting and for the manner in which fibroblasts are used in 
research. 
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Introduction 
The extensive fibrotic stroma associated with pancreatic diseases play an integral role in their 
pathogenesis. Activated fibroblasts constitute the most significant component of disease-associated 
desmoplastic stroma (1). Pancreatic stellate cells (PSCs), a major source of pancreatic fibroblasts, are 
resident lipid-storing cells, which in health are quiescent, and characterized by many lipid droplets 
rich in vitamin A. Pancreatic injury causes the activation of PSCs to myofibroblast-like cells. This is 
associated with loss of cytoplasmic lipid droplets, increased proliferation and enhanced expression 
of α-smooth muscle actin (α-SMA), as well as extracellular matrix (ECM) components (2). Where 
pancreatic injury is long-lasting e.g. in chronic pancreatitis (CP) or pancreatic ductal adenocarcinoma 
(PDAC), persistent fibroblast activation leads to overproduction of collagen, fibronectin, laminin and 
hyaluronic acid resulting in a dense fibrotic meshwork.   
 
In mouse models of pancreatic cancer, PSCs increase tumor growth, promote metastasis, and 
accompany cancer cells to metastatic sites where they stimulate angiogenesis (3). There is evidence 
that the dense collagenous meshwork produced by activated fibroblasts physically prevents drug 
delivery to the tumor cells (4). Moreover, cancer–associated fibroblasts have been reported to 
scavenge the chemotherapeutic drug gemcitabine, reducing the levels of drug available to tumor 
cells (5). On the other hand, depleting pancreatic fibroblasts from PDAC tumors in mice yielded 
aggressive tumors and decreased survival (6,7). Thus, a complex picture emerges of cells with the 
apparent contradictory capabilities of both protecting against tumor aggression and promoting 
tumor progression.  
 
Understanding how best to target disease-associated pancreatic fibroblasts is a priority. An early 
study identified significant overlap in gene expression of desmoplastic stroma from PDAC and the 
fibrous stroma of CP (8). Consistent with this, isolated activated fibroblasts from either CP or PDAC 
share morphological and functional characteristics (9). However, whether pancreatic fibroblasts, 
4 
 
activated in the context of different pancreatic diseases or in culture, are similar or whether they are 
uniquely programmed by their environments remains an unanswered question in the field. 
Answering this question has important implications for how we therapeutically target these cells in 
different diseases and for how pancreatic fibroblasts are used in research.  
 
Using a combination of miRNA and mRNA expression profiling of fibroblasts isolated from PDAC, CP, 
periampullary tumors (PAT) and areas of histologically normal pancreas, followed by comprehensive 
validation, we show that activated fibroblasts derived from different pancreatic disease types are 
distinct.  
 
 
Materials and methods 
  
Pancreatic tissue and blood samples  
Resected pancreatic tissue and blood samples were obtained following the approval of the UK 
Health Research Authority in accordance with the Declaration of Helsinki, including ethical approval 
(London – South East Research Ethics Committee, Ref: 16/LO/1630) and written informed consent, 
from patients undergoing pancreatic surgery at the Royal Liverpool University Hospital. For discovery 
work, activated fibroblasts from areas of diseased pancreas were isolated from patients with 
pancreatic ductal   adenocarcinoma (PDAC, n=6), periampullary tumors (PAT, n=5) comprising 
ampullary and duodenal tumors, and chronic pancreatitis (CP, n=5). Unmatched adjacent-
morphologically normal pancreatic tissue from patients with Mucinous Cystic Neoplasm (n=1), 
intraductal papillary mucinous neoplasm (IPMN) (n=1), PDAC (n=1) and PAT (n=2) was used to isolate 
adjacent-normal pancreatic stellate cells (PSCs). For independent validation fibroblasts were isolated 
in the same manner as the discovery set from an additional 13 patients (PDAC, n=9; CP, n=3 and 
Normal, n=1). Finally, commercially available human primary normal pancreatic fibroblasts (NF; Vitro 
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Biopharma) were also analyzed. A portion of each specimen was formalin-fixed and stained with 
hematoxylin and eosin to confirm the histopathology. 
 
Primary fibroblasts isolation  
Diseased fibroblasts (PDAC, CP and PAT) were isolated from pancreatic tissue using the outgrowth 
method (10) with modifications. Briefly, fibrotic pancreatic tissue, identified following gross analysis 
of the resected specimen by a pathologist, was collected in ice-cold phosphate-buffered saline 
containing 1% penicillin-streptomycin. Tissue was cut into 1-2 mm
3
 pieces, seeded in a six-well cell 
culture uncoated plate in the presence of Iscove's Modified Dulbecco's Medium (IMDM) 
supplemented with 20% FBS, 2% L-glutamine, 1% penicillin-streptomycin and maintained at 37˚C in a 
humidified atmosphere of 5% CO2/95% air until fibroblasts grew out (two to four weeks to reach 
80% confluence). The tissue pieces were removed when fibroblasts reached about 30% confluence. 
The medium was changed twice weekly, and cells were grown to 80% confluence, harvested and 
stored in liquid nitrogen.  
Unmatched adjacent-morphologically normal pancreatic tissue was used to isolate adjacent-normal 
pancreatic stellate cells (PSCs) using the density gradient method (11). Isolated quiescent PSCs were 
cultured in a six-well cell culture uncoated plate (and thus culture-activated) until cells reached 80% 
(two to four weeks) to achieve adequate yield and purity as previously described by Sherman et al 
(12) and are hereafter referred to as normal activated (NA). These cells were cultured in IMDM 
supplemented with 20% FBS, 2% L-glutamine, 1% penicillin-streptomycin and maintained at 37˚C in a 
humidified atmosphere of 5% CO2/95% air. The medium was changed twice weekly, and cells were 
grown to 80% confluence, harvested and stored in liquid nitrogen.   
The commercially available normal fibroblasts (NF) were grown using commercial low serum 
medium (NF-LSM) (MSC-GRO, Vitro Biopharma) and IMDM supplemented with 10% FBS, 2% L-
glutamine, 1% penicillin-streptomycin (NF-HSM) using the same conditions detailed above.  
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For mRNA / miRNA array experiments, diseased fibroblasts, normal activated fibroblasts (NA), and 
commercially available normal fibroblasts (NF) from early passages (P1 or P2) were recovered from 
liquid nitrogen simultaneously and placed in a T75 flask with IMDM supplemented with 10% FBS, 2% 
L-glutamine, 1% penicillin-streptomycin. The media was replenished twice weekly and cells were 
grown to 80% confluence before RNA was isolated as described below.  
 
Cell lines 
Human PDAC cell lines, MIAPaca‐2, Panc‐1 and HeLa were obtained from the American Type Culture 
Collection. Cells were validated by STR profiling and tested for mycoplasma using e-Myco plus 
mycoplasma PCR detection kit (iNTRON Biotechnology) following manufacturer instructions.  
 
Microarray experiments 
Total RNA isolated from the fibroblasts obtained was hybridized onto GeneChip Affymetrix miRNA 
4.0 and Human Transcriptome Array 2.0 Affymetrix. The labelling, hybridization, scanning, and data 
extraction of mRNA and miRNA array experiments were performed at the Centre for Genomic 
Research, University of Liverpool. 
 
Human Transcriptome Array 
50ng of total RNA (free from DNA) was labelled using the Ovation Pico WTA system V2 (NuGen 
Technologies, Inc.). This kit prepares amplified cDNA for gene expression analysis. Following second 
strand synthesis the cDNA was purified using Agencourt RNAClean XP beads prior to SPIA 
amplification. The SPIA amplified cDNA was purified using the Qiagen QIAquick PCR Purification 
system. Utilizing the Encore Biotin Module 5µg of amplified cDNA was fragmented and Biotin-
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labelled before hybridization on Affymetrix GeneChip Human Transcriptome 2.0 arrays (HTA_2.0) 
(Affymetrix, Inc.). Arrays were hybridized for 17 hours at 45˚C and 60rpm in an Affymetrix GeneChip 
hybridisation oven 645. Following hybridization the arrays were washed and stained on an 
Affymetrix GeneChip Fluidics Station 450 using a FS450_0001 script and scanned in an Affymetrix 
Genechip Scanner 3000G. 
 
microRNA array  
130ng of total RNA (free from DNA) was labelled using the FlashTag Biotin HSR RNA Labeling Kit 
(Affymetrix). This process began with a brief tailing reaction followed by ligation of the biotinylated 
signal molecule to the target RNA sample. Biotin-labelled samples and controls were added to a 
hybridization mix and hybridized to Affymetrix GeneChip miRNA 4.0 arrays for 18 hours at 48˚C and 
60rpm in an Affymetrix GeneChip hybridization oven 645. Following hybridization, the arrays were 
washed and stained on an Affymetrix GeneChip Fluidics Station 450 using a FS450_0002 script and 
scanned in an Affymetrix Genechip Scanner 3000G.  
 
Conditioned media experiments using PDAC cell lines 
PANC-1 and MIAPaCa-2 cells were seeded at a density of 7.5 × 10
5
 cells per 75-cm
2
 flasks using 
DMEM + GlutaMAX supplemented with 10% FBS and 1% penicillin-streptomycin. After 24h media 
was replaced and cells were grown for an additional 72h at which point cells had reached 80-90% 
confluence. Conditioned media (CM) was collected and filtered using a 0.22µm filter and stored at -
80˚C until use. Flasks without cells were processed similarly, as controls. Fibroblasts were seeded in 
6-well plates at 8.0 × 10
4
 cells per well using DMEM + GlutaMAX, supplemented with 10% FBS, 1% 
penicillin-streptomycin and after reaching ~70% confluence cells were incubated with CM diluted 1:2 
with fresh DMEM for 48h before RNA was extracted for qRT-PCR analysis.   
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NPPB treatment  
R2796 and R2797 (NA fibroblasts) in addition to R2910 and R3104 (PDAC-associated fibroblasts) 
were seeded on a 24-well plate at 3.0 × 10
4
 cells per well using DMEM + GlutaMAX supplemented 
with 10% FBS and 1% penicillin-streptomycin. The next day, cells were washed with PBS twice and 
further incubated in DMEM + GlutaMAX serum free media supplemented with 1% penicillin-
streptomycin whilst being treated with 100nmol/L of human NPPB (Bachem, Switzerland) and water 
(control) 3 times a day for 48h. This dosing protocol was followed to maintain active levels of NPPB 
in culture (13). 
 
TGFβ1 treatment  
R2796 and R2797 (NA fibroblasts) in addition to R2910, R3104 and R2875 (PDAC-associated 
fibroblasts) were seeded on a 24-well plate at 3.0 × 10
4
 cells per well using DMEM + GlutaMAX 
supplemented with 10% FBS and 1% penicillin-streptomycin. The next day cells were washed with 
PBS twice and further incubated in DMEM + GlutaMAX serum free media supplemented with 1% 
penicillin-streptomycin whilst being treated with 5ng/ml or 10ng/ml of human TGFβ1 (Millipore) and 
water (control) for 24h and/or 48h.  
 
Wnt pathway activation  
Wnt pathway stimulation was achieved using an L-Wnt-3A cell line (14). In order to generate L-Wnt-
3A conditioned media (CM) 1 × 10
6
 cells per T75 flask were seeded using DMEM + GlutaMAX, 10% 
FBS, 1% geneticin. After 24 hours media was replaced and cells were grown for an additional 72h at 
which point cells had reached 80-90% confluence. Then, CM was collected and filtered using a 
0.22µm filter. In addition, a flask without cells was also filled with culture medium for 72h to 
generate control media and processed as before. R2796, R2797 and R2951 (NA fibroblasts) in 
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addition to R3008 and R3072 (PDAC-associated fibroblasts) and R3030 and R334 (PAT-associated 
fibroblasts) were seeded at 50,000 cells on a 6-well plate for 24h before media was replaced with L-
Wnt-3A CM for an additional 24h before RNA was extracted to measure AXIN2 levels using qRT-PCR. 
 
TNC knockdown and collection of conditioned media 
Immortalized PDAC-associated and normal activated fibroblasts were seeded on a 6-well plate at 6 × 
10
4
 cells per well in DMEM + GlutaMAX supplemented with 10% FBS without antibiotics. After 24h 
cells were transfected using Opti-MEM I reduced serum media followed by addition of 
Lipofectamine (ThermoFisher Scientific) according to manufacturer’s instructions. Two different 
siRNAs targeting TNC (ON-TARGET plus siRNA Human TNC: #J-009298-07-0005 and #J-009298-05-
0005) or a non-targeting control (ON-TARGET plus control pool: #D-001810-10-20) (Dharmacon) with 
a final siRNA concentration of 30nM were used. The day after the transfection medium was replaced 
by serum-free media (DMEM + GlutaMAX without antibiotics). Cells were then grown for a further 
48h to reach 80-90% confluence. Conditioned media (CM) was collected and filtered using a 0.22µm 
filter and stored at -80˚C until use for cell migration and proliferation experiments. In addition, cells 
were lysed to obtain protein.  
 
Migration assays 
Transwell cell migration assays were performed using 8μm pore size ThinCertTM cell culture inserts 
(greiner bio-one) in a 24-well format. MIA PaCa-2 cells were preincubated in serum-free DMEM + 
GlutaMAX media overnight. 100 µl of cell suspension containing 6 × 104 cells were placed in the 
insert. The outer chamber was filled with 500µl of conditioned media from the fibroblasts TNC 
knockdown experiment including controls (diluted 1:2 with DMEM + GlutaMAX and supplemented 
with 2% FBS) and cells were allowed to migrate for 24h. After incubation, non-migrating cells were 
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removed from the top of the membrane with cotton swab. Migrated cells were fixed with 70% 
ethanol and stained with 0.3% crystal violet. Quantification of migration was performed using 
QuPath (version 0.2.0-m2) (15). Images were taking using a Nikon Eclipse E600 at 4x. The area of 
migrated cells (crystal violet) and cell-free area were quantified using the pixel classifier tool 
(applying the Random Trees classifier and using a downsample resolution between 4 and 8). Cell 
migration of treated cells was expressed as a percentage of control.   
 
Proliferation assays 
MIA PaCa-2 cells were plated on a 96-well plate at 5 × 10
3
 cells per well using DMEM + GlutaMAX 
supplemented with 10% FBS. The following day cells were washed twice with PBS and treated with 
conditioned media from the normal or PDAC-associated fibroblasts TNC knockdown experiment 
including controls (diluted 1:2 with DMEM + GlutaMAX and supplemented with 2% FBS).  After 48h, 
cell proliferation was measure using the EZ4U assay system (Biomedica) and a Multiskan FC 
microplate reader (ThermoFisher Scientific) according to manufacturer’s instructions.  
 
microRNA mimics  
Immortalized PDAC-associated fibroblasts were seeded on a 24-well plate at 2.0 × 10
4
 cells per well 
using DMEM + GlutaMAX supplemented with 10% FBS without antibiotics. After 24h miRNA mimics 
including hsa-miR-137 and hsa-miR-212-3p (30nM) (Qiagen) or AllStars off-target control (30nM) 
(Qiagen) were diluted in Opti-MEM I reduced serum media (ThermoFisher Scientific) followed by 
addition of HiPerFect (Qiagen) transfection reagent according to manufacturer’s instructions. 
Complexes were added drop-wise onto the cells and incubated for 48h before RNA or condition 
media was extracted for qRT-PCR and immunoblotting respectively.  
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Tissue microarray (TMA) construction 
Formalin-fixed paraffin-embedded (FFPE) PDAC and CP specimens were obtained from the Royal 
Liverpool University Hospital. Matched haematoxylin and eosin stained slides were marked by a 
specialist histopathologist (FC) for areas of tumor and fibrosis in the PDAC and CP cases respectively. 
Two TMAs were constructed from PDAC specimens, PDAC TMA #1 (n=41) and PDAC TMA #2 (n=48), 
with three 0.6mm cores extracted per patient. One TMA was constructed from CP specimens (n=47), 
with four 0.6mm cores extracted for each patient.  
 
Serum biomarker analysis by multiplex and enzyme-linked immunosorbent assay (ELISA) analysis 
A discovery cohort of serum samples were obtained from patients undergoing pancreatic surgery at 
the Royal Liverpool University Hospital (termed UoL, n=65) and healthy donors (n=15). The discovery 
cohort was subjected to multiplex quantification of 101 cancer-associated proteins (Human 
OncologyMAP® v1.0, Myriad Rules-Based Medicine).  
ELISAs for TNC (Large FNIII-B, IBL international) were performed according to the manufacturer’s 
instructions and assessed for reproducibility in the UoL discovery cohort (n=75). Upon confirmation, 
TNC concentrations were determined in an independent cohort of UoL samples (n=155). 
 
Statistical Analysis  
All statistical test were performed using R software V.3.5.2. Continues variables were expressed as 
mean±SEM and compared using a one-way ANOVA or Kruskal Wallis Test, paired or unpaired t-test 
and Mann-Whitney U test as appropriate; categorical variables were compared using the chi-
squared
 
test. Results were considered significant at p < 0.05. 
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Supplemental Methods are described in Supplementary Material and Methods 
 
Results  
Disease-associated fibroblasts from pancreatic pathologies show distinct gene expression profiles 
To determine the extent to which fibroblasts are programmed by their distinct disease environments 
we isolated pancreatic fibroblasts and analyzed uniquely low passage (P1 or P2) from a total of 34 
individuals, enabling us to compare PDAC, PAT, CP and adjacent normal-derived cells (Figure 1A and 
Supplementary Table 1). Consistent with others, we found that disease-associated fibroblasts 
exhibited myofibroblast-like morphology with characteristic expression of α-SMA, desmin, vimentin 
(Figure 1B) and other common markers of fibroblasts (Supplementary Figure 1A). One day post-
isolation, primary normal PSCs contained characteristic lipid droplets as measured by Oil Red O 
(Figure 1B), however, following expansion in culture, they became activated, gaining expression of α-
SMA, and are hereafter called normal activated (NA). None of the isolated cells expressed 
macrophage (CD68) or epithelial (pan-cytokeratin and EPCAM) (Figure 1B and Supplementary Figure 
1A) markers. KRAS mutational status was successfully determined for 33 isolates. One isolate, from a 
PDAC tumor, was found to be heterozygous for mutant KRAS (G12R) and was excluded from the 
study. 
 
mRNA and miRNA gene expression profiles of isolated fibroblasts, as well as commercially available 
normal fibroblasts (NF) grown in low or high serum, were generated. qRT-PCR analysis of eight 
randomly selected genes was undertaken to validate our microarray profiling experiments. The 
expression patterns observed in array data for four mRNAs (Supplementary Figure 1B) and two 
miRNAs (Supplementary Figure 1C) were confirmed by qRT-PCR in the discovery samples, and for a 
further two mRNA candidates (Supplementary Figure 1D) in analyses which included independent 
primary fibroblasts (Independent set, Supplementary Table 1).  
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Principal component analysis (PCA) of both mRNA (Figure 1C) and miRNA (Figure 1D) expression 
showed evidence of clustering based on the disease group from which fibroblasts were derived, 
indicating differences in the nature of activated fibroblasts between disease types.   
 
To explore this further, we compared the extent to which fibroblasts programmed by different 
pancreatic diseases differ from normal activated fibroblasts. We found 1,469 genes differentially 
expressed between PDAC-associated fibroblasts and NA, compared to only 776 genes differentially 
expressed between PAT-associated fibroblasts and NA. This suggested that distinct malignancies 
program fibroblasts differently. CP fell between PDAC and PAT with 925 differentially expressed 
genes compared to NA (Figure 1E). Surprisingly, only 24% of genes were commonly dysregulated 
across the three different diseases compared to NA (Figure 1E), although this rose to 48.5% when 
the disease-associated fibroblasts groups were compared to NF (Supplementary Figure 2A). 
 
Almost one third (32.2%) of genes significantly altered between PDAC and NA were unique to this 
comparison group while only 6.6% and 7.3% respectively were exclusive for the CP versus NA and 
PAT versus NA comparisons (Figure 1E). Interestingly, PDAC and CP shared over 41.5% of genes 
dysregulated when compared to NA, indicating similarities in the programming of fibroblasts by 
these disease types.  
 
Consistent with recent reports (16-18), the most enriched canonical pathways associated with 
disease-associated fibroblasts compared to NA were phagosome maturation, autophagy and 
endocytosis signaling (Figure 1F). The most common biological functions differentially regulated 
between disease-associated fibroblasts and NA or NF corresponded to cell movement and migration 
with key upstream regulators such as TNF, TP53 and TGFβ1 (19-21) altered in these comparison 
groups (Supplementary Figure 2B, 2C).  
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Only five miRNAs were significantly dysregulated between PDAC-associated fibroblasts and NA 
(Supplementary Figure 2D). Similarly, five miRNAs were altered between CP and NA, and four of 
these were also dysregulated between PDAC-associated fibroblasts and NA. Fibroblasts programmed 
by PAT had two dysregulated miRNAs compared to NA, one of which was unique to PAT (hsa-miR-
92a-1-5p), and the other, hsa-miR-138-1-3p, was also dysregulated in CP and PDAC. Nine miRNAs 
were dysregulated in all three-disease types compared to NF (Supplementary Figure 2E).  
 
Taken together, our data indicate that while there is commonality between fibroblasts cultured from 
different pancreatic disease types or normal tissue, the groups are distinct. Given that our PCA 
analysis showed NA to be more closely related to the other primary fibroblast isolates than the 
commercially available NF were, we focused subsequent analyses on NA.  
 
PDAC-associated fibroblasts are less responsive to an anti-fibrotic stimulus and more responsive to 
positive regulators of fibroblast activation than normal activated fibroblasts 
Next we sought to understand how PDAC-associated fibroblasts differed from all other disease-
associated or NA fibroblasts. Our analysis (Figure 2A) revealed 224 differentially regulated genes 
between PDAC and PAT-derived fibroblasts and 90 differentially regulated genes between PDAC and 
CP. Twelve genes were uniquely dysregulated in PDAC-associated fibroblasts compared to all other 
groups. One of these, NPPB, also known as brain natriuretic peptide was amongst the most highly 
up-regulated transcripts between groups in both discovery (Figure 2B), and validation samples 
(Supplementary Figure 2F). Analysis of data from the Gene Expression Omnibus database (Figure 2C, 
https://www.ncbi.nlm.nih.gov/geo/geo2r/, GEO accession: GSE21440) (22) corroborated our 
observation. NPPB mRNA levels in fibroblasts derived from PDAC (CAF, n=9) were higher than from 
control fibroblast lines (HPNE and NF1-3) and from an IPMN (SC-2) (22).  
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We postulated that the high levels of NPPB in PDAC-associated fibroblasts were the result of in vivo 
tumor-stroma paracrine signaling prior to fibroblast isolation. Indeed, stimulating primary PDAC-
derived fibroblasts with conditioned medium from PANC-1 or MIAPaCa-2 cells led to increased NPPB 
transcription in the fibroblasts (Figure 2D). By contrast, NPPB expression was undetectable in two 
independent isolates of NA fibroblasts, and consistently remained undetectable after treatment with 
conditioned medium from pancreatic cancer cell lines. This suggested differences in the ways in 
which PDAC- and NA-fibroblasts respond to external stimuli. Curiously, for one of the most highly 
regulated molecules in PDAC-associated fibroblasts, NPPB’s function may relate to reducing fibrosis. 
NPPB is reported to have anti-fibrotic properties in the heart (13) and kidney (23) and inhibits liver 
fibrosis by preventing activation of hepatic fibroblasts (24). We examined whether incubation of 
activated pancreatic fibroblasts with NPPB could reverse their activation, leading to diminished α-
SMA gene (ACTA2) expression. To avoid bias, we selected NA and PDAC-associated fibroblasts 
respectively with high (R2796 and R2910) and low (R2797 and R3104) pre-treatment α-SMA levels 
(Figure 2E). Treatment of fibroblasts with recombinant NPPB protein led to a decrease in α-SMA 
expression in both NA and PDAC high and low α-SMA expressers (Figure 2F), although the greatest 
anti-fibrotic effects were observed in NA. 
 
We next evaluated positive regulators of fibroblast activation. Consistent with its prominent role in 
pancreatic fibrosis (25), Ingenuity Pathway Core Analysis identified TGFβ1 among the top three 
activated upstream regulators in pancreatic disease-associated fibroblasts compared to NA (Figure 
2G, left panel). Treatment of high (R2796 and R2910) and low (R2797, R3104, R2875) α-SMA 
expressing fibroblasts with TGFβ1 increased the activation state, as measured by α-SMA expression, 
in both PDAC- and NA-associated fibroblasts (Figure 2G, right panel), with a significant induction of 
α-SMA observed in PDAC-derived fibroblasts. The canonical Wnt pathway mediates fibroblast 
activation through interaction with TGFβ (26). The molecular activity predictor tool in IPA predicted 
that the Wnt pathway was activated in PDAC-associated fibroblasts compared to NA (Figure 2H). To 
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evaluate Wnt signaling, we incubated NA, PDAC-associated fibroblasts and PAT-associated 
fibroblasts with conditioned medium from a cell line that constitutively secretes Wnt-3A (14). The 
resulting induction of AXIN2 expression was observed in both NA and the cancer-associated 
fibroblasts, with the highest induction seen in cancer-associated fibroblasts (Figure 2I). Collectively, 
our data on NPPB, TGFβ and WNT signaling demonstrate that fibroblasts activated in vitro by the 
culture process (NA) are functionally distinct from fibroblasts programmed in vivo by cancer. PDAC-
associated fibroblasts were less readily inactivated than NA, and considerably more responsive to a 
positive trigger of activation. 
 
Disease-associated fibroblasts from distinct pancreatic disorders exhibit subtype-specific genetic 
profiles  
We next narrowed our focus to fibroblasts programmed by pancreatic diseases, examining 
differences between fibroblasts from PDAC, CP and PAT (Figure 3A). The greatest overlap in gene 
expression was between PDAC and CP with only 90 differentially expressed genes. By contrast, PDAC 
and PAT differed by 224 genes and there were 272 genes differentially regulated between PAT and 
CP. Interestingly, the most enriched pathway identified by IPA, the Hepatic Stellate Cell Activation 
Pathway was not significantly differentially enriched between PDAC and CP, indicating commonality 
between the activation of fibroblasts in these two disease types (Figure 3B and 3C). By contrast, this 
pathway was significantly up-regulated in PDAC compared to PAT, and downregulated in PAT 
compared to CP (Figure 3B and 3C), highlighting differences in the way in which PAT fibroblasts are 
activated compared to both PDAC and CP. Gene expression alterations in this pathway can be 
attributed to upstream regulators such as TGFβ1, p38 MAPK, MAPK and HIF1A, (27,28) which were 
significantly modulated between these comparison groups (Supplementary Table 2). Four of the top 
eight pathways identified by IPA were immune-related (Figure 3B). Of note, the genes most 
commonly dysregulated in these pathways belonged to the major histocompatibility complex (MHC) 
class I, namely HLA-A, HLA-B, HLA-C, which were downregulated in PDAC-versus-CP and in PDAC-
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versus-PAT (Figure 3D). In addition, the Cell Cycle Control of Chromosomal Replication and the ATM 
Signaling pathways, which showed no differences between PDAC and CP (Figure 3B) were 
significantly dysregulated in PAT compared to CP (Figure 3E and 3F).  
 
Taken together, these data indicate significant differences in the pathways activated in disease-
associated pancreatic fibroblasts from different pathologies. 
 
Tenascin C levels are elevated in PDAC-associated fibroblasts compared to CP- associated 
fibroblasts  
While this study was ongoing, in parallel research we sought differences in serum proteins from 
patients with CP and PDAC using a multiplex quantification of 101 cancer-associated proteins 
(Myriad Rules-Based Medicine’s Human OncologyMAP® v1.0 platform). Apart from the well-
established carbohydrate antigen tumor markers, CA19-9 and CA125, only circulating Tenascin C 
(TNC) was significantly upregulated in PDAC compared to CP patients in discovery analysis (Figure 
4A) and in an independent validation cohort (Figure 4B, Supplementary Table 3). We considered this 
finding highly significant, as circulating proteins capable of distinguishing CP from PDAC are 
extremely rare. Moreover, TNC is not widely expressed in adults, except in the extracellular matrix of 
diseased or injured tissues. Our serum data drove us to question whether TNC expression was more 
pronounced in fibroblasts isolated from PDAC than CP. Although not identified as significantly 
differentially expressed using the stringent criteria of our array analysis, our array data nonetheless 
indicated lower TNC in CP than in PDAC (Figure 4C). Moreover, RT-PCR confirmed that TNC 
transcripts were significantly upregulated in PDAC-associated fibroblasts compared to CP-associated 
fibroblasts (Figure 4D). Immunohistochemistry for TNC in resected PDAC and CP specimens was 
performed using the same antibody we used in our serum analysis (clone 4C8MS, TNC-FN III-B) and 
revealed heterogeneous TNC staining, with TNC protein variously present in areas of stroma, benign 
ducts and tumor cells. Notably, regions of strong staining were observed in the desmoplastic stroma 
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of tumors even when neighboring epithelia lacked expression (Figure 4E). Tissue microarrays (TMAs) 
from PDAC and CP cases (Supplementary Table 4) revealed more frequent TNC protein in the 
stromal compartments of PDAC cases compared to CP cases (60.4% compared with 13.9%, 
respectively, Figure 4F). TNC-null mice exhibit attenuation of skin and lung fibrosis (29), and TNC has 
recently emerged as a key regulator of CAFs as part of a Twist1-Prrx1-TNC feedback loop that 
operates as an ON/OFF switch regulating fibroblast activation (30). We measured the ratio of α-
smooth muscle actin (α-SMA) to collagen, defined as the activated stroma index (31) (Figure 4G). 
PDAC cases with TNC
+
 stroma had significantly greater activated stroma index values than those 
lacking stromal TNC (Figure 4H). RNA in situ hybridization for TNC mRNA showed that of 79 PDAC 
cases examined, 82.3% contained TNC mRNA-expressing cells in the stroma, compared to 47.2% of 
CP cases (n=36; Figure 4I and J). Together, our data indicate that fibroblasts programmed in the 
context of CP are distinct from those programmed in the context of PDAC, and this is exemplified by 
the lower expression of TNC in CP-associated fibroblasts than PDAC fibroblasts.  
 
Depletion of TNC in PDAC-associated fibroblasts promotes migration of cancer cells  
We next sought to understand the functional significance, for PDAC cells, of high TNC expression in 
PDAC-associated fibroblasts (Figure 5A, 5B and 5C). We found that conditioned media from TNC-
depleted CAFs but not TNC-depleted NA fibroblasts (Figure 5D) caused significantly greater 
migration of MIA PaCa-2 cells when compared to conditioned media from control siRNA-treated 
fibroblasts. Additionally, we found a modest 8% increase in MIA PaCa-2 cell proliferation following 
exposure to conditioned media from TNC-depleted CAF but not TNC-depleted NA fibroblasts (Figure 
5E). Our data indicate that CAF-derived TNC decreases the migration of PDAC cells and has a minor 
negative effect on PDAC cell growth.  
Finally, given that TGFβ1 was one of the top activated upstream regulators in pancreatic disease-
associated fibroblasts compared to NA (Figure 2G), along with the well-established function of TGFβ 
in several key steps of tumorigenesis (32), we questioned whether TNC levels in pancreatic 
19 
 
fibroblasts influenced TGFβ1 levels. We found that TNC depletion in CAF (Figure 5F) but not NA 
(Figure 5G) was accompanied by significant reduction in TGFβ1 expression. Taken together, our data 
support the notion that TNC deficiency in CAFs promotes migration of cancer cells, and that this is 
associated with a parallel reduction in TGFβ1 expression. 
 
miR-137 regulates TNC expression 
To explore mechanisms underlying the difference in expression of TNC in PDAC-associated stroma 
compared to CP stroma, an in silico analysis was performed to identify miRNAs with the potential to 
target the 3' untranslated region (UTR) of TNC mRNA using http://www.miRNA.org. Of 24 candidate 
miRNAs, two, miR-212-3p and miR-137, tended towards downregulation in PDAC compared to CP 
(Figure 6A and 6B), the inverse of the observed TNC mRNA levels in PDAC and CP (Figure 4C and 4D). 
One potential binding site in the UTR of TNC mRNA was identified for hsa-miR-212-3p and two sites 
were identified for hsa-miR-137 and ranked by mirSVR scoring (Figure 6C). To test whether these 
microRNAs regulated the expression of TNC, PDAC-associated fibroblasts were treated with mimics 
of the selected candidate miRNAs. Transfection of a miR-137 mimic but not a miR-212-3p mimic 
significantly reduced TNC expression levels, at both the mRNA (Figure 6D) and protein level (Figure 
6E). A luciferase reporter assay utilizing the TNC 3' UTR binding site for miR-137 with the best 
mirSVR score value (position 444; mirSVR -1.2304), confirmed that miR-137 targets this region 
(Figure 6F). Notably, the decrease of luciferase activity was abolished when the TNC 3' UTR target 
site was mutated. Our data point towards miRNA-mediated fine-tuning of pancreatic fibroblast gene 
expression contributing to distinct fibroblasts programing between CP and PDAC.  
To determine whether TGFβ1 controls the miR-137-TNC axis, we treated CAF and NA with TGFβ1 
and measured the expression of both TNC and miR-137. We observed a significant increase in TNC 
expression in both CAF and NA following TGFβ1 treatment (Figure 6G). Moreover in NA, TGFβ1 
treatment was accompanied by significant down-regulation in the expression of miR-137 (Figure 6H), 
demonstrating that TGFβ can control this axis. Down-regulation of miR-137 was not observed in 
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CAFs following treatment by TGFβ1. Thus it would appear that other factors may also underpin the 
regulation of this axis. 
 
Discussion 
In the present study, we show the first direct comparison of pancreatic fibroblasts isolated from 
distinct pancreatic diseases, we provide evidence that pancreatic fibroblasts are programmed by 
their unique disease-specific environments and that their distinct gene expression persists following 
isolation. The challenges associated with isolating and characterizing human primary pancreatic 
fibroblasts has led to this fundamental question remaining unanswered until now. Although all of 
the disease-associated fibroblasts compared in our study exhibited myofibroblast-like morphology 
and expressed characteristic markers of activation, less than one quarter of differentially expressed 
genes were commonly shared between disease groups, compared to NA. When comparisons were 
restricted to disease-associated fibroblasts only, less than one percent of differentially expressed 
genes were commonly altered across disease types. This argues against a single common phenotype 
of pancreatic fibroblast activation and emphasizes the importance of using appropriate fibroblasts to 
address disease-specific research questions. Similarly, all of the primary fibroblasts isolated for this 
study, including NA, were subjected to culture, prior to RNA extraction for gene profiling. Whilst one 
might expect this to have a ‘normalizing’ effect, isolated fibroblasts exhibited distinct characteristics 
of the disease group to which they belonged. Notably, NA were more responsive than PDAC-
associated fibroblasts to the anti-fibrotic effects of NPPB, (13,23,24) showing large reductions of the 
fibroblast activation marker α-SMA. Similarly, tumor fibroblasts responded with greater intensity 
than NA to the activation stimuli of TGFβ and WNT signaling.  
 
The global impact of microRNA regulation in quiescent versus activated pancreatic stellate cells has 
thus far been performed in rats only (33). Our comparison of primary human NA fibroblasts with 
human disease-activated fibroblasts revealed only a small proportion of differentially expressed 
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miRNAs, with no difference found between PDAC and CP or PDAC and PAT. This reflects a tight 
regulation of miRNAs across pancreatic disease fibroblasts in contrast to the high number of mRNA 
transcripts differentially regulated.  
 
The activation of PAT-associated fibroblasts was distinctly different from that of PDAC-associated 
fibroblasts as indicated by the up-regulation of genes associated with the Hepatic Stellate Cell 
Activation Pathway in PDAC-associated fibroblasts compared to PAT- but not CP-associated 
fibroblasts. Ampullary and duodenal cancer-associated fibroblasts are hardly characterized and 
warrant further study. Overlap observed between PDAC- and CP-associated fibroblasts may reflect 
the fact that both diseases can present concurrently, and that fibroblasts in the context of PDAC are 
educated by both the tumor and by CP. Nonetheless there were significant differences between 
PDAC- and CP-derived fibroblasts, as exemplified by TNC. The higher TNC transcript and protein 
levels in PDAC-derived fibroblasts and PDAC resected specimens compared to CP and the positive 
link between TNC and activated stroma suggests enhanced fibroblast activation in PDAC versus CP in 
our study.  
 
The consequences, however, of high fibroblast levels of TNC on cancer cell behavior has hardly been 
examined to date. Our finding that conditioned medium derived from TNC-depleted PDAC-
associated fibroblasts enhanced the motility of Mia PaCa-2 cells is intriguing, and implies that the 
high levels of TNC in PDAC-associated fibroblasts may serve to repel tumoral cells. Consistent with 
this, TNC knock-out in breast carcinomas allowed the attraction of macrophages (34). 
 
Uncovering miR-137 as a regulator of TNC in disease-associated fibroblasts provides a potential 
candidate for targeting TNC. Previous studies have reported down-regulation of miR-137 in 
pancreatic cancer tissues compared to their normal counterpart with its overexpression leading to 
inhibition of cancer cell invasion and promotion of senescence (35,36). In a study of acute lung 
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injury, TNC-null lung fibroblasts exhibited impaired responsiveness to TGFβ (37). Our findings that 
TNC depletion diminishes TGFβ1 expression in pancreatic CAF while TGFβ1 stimulation of CAFs and 
NA increased TNC expression evidences the important interplay between TNC and TGFβ1 in 
pancreatic fibrosis.  Finally, the identification of TNC as a biomarker with potential to distinguish 
PDAC from CP warrants further investigation as such circulating biomarkers are lacking.  
 
In conclusion, we present evidence that in vivo programming of human fibroblasts is disease-specific 
and is, at least to an important extent, maintained in culture. Single cell technologies have helped 
elucidate how stromal CAFs contribute to proliferative and invasive transcriptional programs of 
PDAC cells, with CAF-secreted TGFβ identified as a key mediator of PDAC cell heterogeneity (38). 
Moreover, the heterogeneity of human PDAC-associated fibroblasts themselves has been described, 
with CAFs exhibiting myofibroblast (myCAF), inflammatory (iCAF) or antigen presenting (apCAF) 
phenotypes (39,40). Future work addressing specific subpopulations of pancreatic fibroblasts from 
different pancreatic diseases are now required. The prevailing perception that activated pancreatic 
fibroblasts are a uniform entity that can be used interchangeably in research requires revision. 
Furthermore, the development of treatments should take into consideration disease-specific 
features of activated pancreatic fibroblasts.  
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Figure Legends:  
 
Figure 1. Isolation, characterization and clustering by gene expression profiling of pancreatic 
fibroblasts. (A) Schematic showing fibroblast isolates from different pancreatic diseases using the 
outgrowth (top) or from unmatched normal appearing tissue using the density gradient methods 
(bottom) including the total number of isolates per fibroblast type (discovery set plus independent 
set). (B) Representative images of primary PDAC-associated fibroblasts confirming expression of α-
SMA, desmin and vimentin. Fibroblasts did not express CD68 or cytokeratin (Scale bar=50µm). In 
addition, image shows a primary normal PSC containing lipid droplets visible by oil-red O staining 
one day after isolation. (C and D) Principal component analysis with 25,195 gene transcripts (C) and 
6,631 microRNA genes (D) separated samples into 5 subsets. Each sphere (PDAC=6, CP=5, PAT=5 and 
NA=5) represents one primary sample. Commercial primary normal fibroblasts (NF) cultured with 
high serum medium (HSM) or low serum medium (LSM) were analyzed in triplicate. (E) Venn 
diagram depicting the number of differentially expressed genes (mRNA array) between disease-
associated fibroblasts from PDAC, CP and PAT versus NA fibroblasts, including the number of genes 
up- or down-regulated per contrast (the percentage is indicated in the parenthesis) (F) Top canonical 
pathways enrichment analysis of differentially expressed genes in all disease-associated fibroblasts 
versus NA fibroblasts, performed using Ingenuity Pathway Analysis. Fisher’s exact test was used to 
determine P-values, with significance set at p=0.05 which translates to –log (P value) of 1.3. 
 
Figure 2. PDAC-associated fibroblasts display greater resistance to the anti-fibrotic effects of NPPB 
and greater responsiveness to TGFβ1 and WNT signaling compared to NA. (A) Venn diagram 
depicting the number of differentially expressed genes (mRNA array) between PDAC-associated 
fibroblasts and the other groups. The twelve genes dysregulated between PDAC and all other groups 
are named, with NPPB highlighted in red as the most up-regulated gene in the list. (B) NPPB mRNA 
array expression measured as Robust Multi-array Average (RMA) in discovery fibroblast isolates 
(PDAC=6, CP=5 and PAT=5) and normal PSC culture-activated as described in material and methods 
(NA=5). (C) NPPB mRNA expression values from Gene Chips data in pancreatic ductal 
adenocarcinoma- (CAF), chronic pancreatitis- (NF1-3), pancreatic IPMN tumor- (SC-2) and normal 
pancreas immortalized-associated fibroblasts (HPNE). Data collected from GEO database accession 
numbers: GSM535920 to GSM535931 (D) qRT-PCR analysis of NPPB expression levels in PDAC-
associated fibroblasts (PDAC-F: R2928 and R2875) and NA-associated fibroblasts (NA-F: R2796 and 
R2797) following incubation for 48 hours with conditioned media from PANC-1 and MIA PaCa-2 cells. 
Expression was normalized to GAPDH using unconditioned DMEM as control. Data are shown as 
mean ±SEM; n=3 independent experiments; P-value determined by one-way ANOVA with post-hoc 
Dunnett’s test. n.d.= non-detectable expression (E) qRT-PCR analysis of ACTA2 expression levels in 
discovery and independent fibroblast samples. Two PDAC- (R2910 and R3104) and two NA-
associated fibroblasts (R2796 and R2797) isolates are highlighted and analyzed in (F) by qRT-PCR for 
ACTA2 after incubation with recombinant human NPPB for 48 hours. Expression levels were 
compared to control (DMEM) and normalized to GAPDH. Error bars depict mean ±SEM of technical 
replicates from two NA- and two PDAC-associated fibroblast isolates. P-value determined by 
unpaired t-test using DMEM as control.  (G) The top 5 upstream regulators (with their predicted 
activation state) significantly enriched in all disease-associated fibroblasts versus NA fibroblasts, as 
determined using IPA (left panel). qRT-PCR for ACTA2 after incubation with recombinant human 
TGFβ1 for 24 hours. Expression levels were compared to control (DMEM) and normalized to GAPDH. 
Error bars depict mean ± SEM of technical replicates from two NA- (R2796 and R2797) and three 
PDAC-associated fibroblast isolates (R2910, R3104 and R2875). P-value determined by unpaired t-
test (right panel). (H) Network analysis employing the IPA molecular activity prediction tool to assess 
directionality of changes in the Wnt signaling pathway for differentially expressed genes in all 
disease-associated fibroblasts versus NA fibroblasts.  (I) qRT-PCR analysis of AXIN2 expression levels 
following incubation with CM from L-Wnt-3A mouse fibroblast cell line for 24 hours. Expression 
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levels were compared to unconditioned media as control (DMEM) and normalized to GAPDH. Error 
bars depict mean ± SEM of technical replicates from three NA- (NA-F: R2796, R2797 and R2951), two 
PDAC- (PDAC-F: R3008 and R3072) and two PAT-associated fibroblasts (PAT-F: R3030 and R3334). P-
values determined by unpaired t-test. 
 
Figure 3. Diseased pancreatic fibroblasts retain identity ex vivo. (A) Venn diagram depicting the 
number of differentially expressed genes (mRNA array) between disease-associated fibroblast 
groups including the number of genes up- or down-regulated per contrast (the percentage is 
indicated in the parenthesis) (B) Top canonical pathway enrichment analysis of differentially 
expressed genes between disease-associated fibroblast groups using IPA comparison analysis. 
Fisher’s exact test was used to determine P-values, with the dashed line indicating p<0.05. (C-F) Fold 
change of gene expression in selected pathways for contrasts analyzed in B.  
 
Figure 4. High levels of TNC identified in primary PDAC- compared to CP- associated fibroblasts 
reflect levels present in tissue and blood. (A) Serum levels of TNC in the discovery cohort of samples 
collected at the Royal Liverpool University Hospital, as measured by Myriad RBM’s Human Oncology 
MAP®. Samples were obtained from individuals with PDAC with or without obstructive jaundice 
(PDAC high bilirubin and PDAC low bilirubin, n=15 and n=20 respectively), as well as healthy 
individuals (n=15) and individuals with benign biliary obstruction (n=10) and CP (n=15). P-values 
determined by Mann-Whitney U test. (B) Serum levels of TNC in independent samples from 
individuals with PDAC and high bilirubin (n=35), PDAC and low bilirubin (n=30), benign biliary 
obstruction (n=27) and CP (n=35), as well as healthy individuals (n=28), as measured by ELISA. P-
values determined by Mann-Whitney U test. (C) TNC mRNA array expression measured as Robust 
Multi-array Average (RMA) in discovery fibroblast isolates (PDAC n=6, CP n=5). (D) qRT-PCR analysis 
of TNC expression in discovery and independent PDAC- (n=15) and CP-associated (n=8) fibroblasts. 
Expression was normalized to GAPDH using CP-associated fibroblasts as control. P-value determined 
by Mann–Whitney U test. (E) Representative image of TNC protein immunostaining in PDAC and CP. 
Scale bar=100µm (low magnification, left image; high magnification of dashed line, right image). (F) 
Proportion of PDAC (n=53) and CP (n=36) patients with TNC protein expression in the fibrotic 
stroma, as measured on a tissue microarray. P-value determined by chi-squared test. (G) Example of 
color deconvolution of α-SMA- and Masson’s trichrome-stained PDAC tissue for calculation of 
activated stroma index (ASI). Scale bar=100µm. (H) ASI in PDAC cases (n=24) in G classified by TNC 
stromal protein expression. P-value determined by Mann–Whitney U test. (I) Representative image 
of TNC mRNA expression in PDAC stroma as determined by RNA in situ hybridization. Scale 
bar=25µm. (J) Proportion of PDAC (n=79) and CP (n=36) patients with TNC RNA expression in the 
fibrotic stroma, as measured on a tissue microarray. P-value determined by chi-squared test. 
 
Figure 5. TNC gene silencing in PDAC-associated fibroblasts leads to a diminished TGFβ1 expression 
and promotes migration of pancreatic cancer cells. (A and B) Experimental design detailing the 
collection of conditioned media from PDAC-associated fibroblasts and normal activated (NA) 
fibroblasts (A) to study the functional significance of stromal TNC on MIA PaCa-2 cells using a 
transwell cell migration assay (B). The images depict representative photographs of transwell 
migration assays conducted on MIA PaCa-2 cells with conditioned media from PDAC-associated 
fibroblasts treated with non-targeting control siRNA and two different siRNAs targeting TNC (n=7). 
Cell migration was quantified using QuPath. CM=conditioned media (C) Representative immunoblot 
analysis after TNC knockdown in PDAC-associated fibroblasts and normal activated fibroblasts to 
confirm effective knockdown before cell migration or proliferation experiments were conducted. β-
actin was used as a loading control. (D and E) Cell migration (D) and proliferation (E) of MIA PaCa-2 
cells following treatment with conditioned media from normal activated and PDAC-associated 
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fibroblasts with siRNA-depleted TNC. Data are expressed as mean percentage of migration or 
proliferation relative to control ±SEM; for the migration assays PDAC=7 and NA=6 independent 
experiments were performed and for proliferation PDAC=4 and NA=2 independent experiments 
were completed.  P-value determined by t-test assuming unequal variance. (F and G) Representative 
immunoblot analysis of TGFβ1 after TNC knockdown in PDAC-associated fibroblasts (F) and normal 
activated fibroblasts (G). Densitometry quantification of TGFβ1 normalized to β-actin is shown for 
each fibroblast type analyzed (n=2). P-value determined by Student’s t-test  
 
Figure 6. TNC is modulated by mir-137 and TGFβ1 in pancreatic fibroblasts. (A and B) Gene array 
expression data of hsa-miR-212-3p and hsa-miR-137 generated using Robust Multi-array Average 
(RMA) from discovery fibroblast isolates (PDAC=6, CP=5). Data are shown as mean ±SEM. (C) 
Potential binding sites (bases in bold) of hsa-miR-212-3p and hsa-miR-137 predicted in the 3’UTR of 
TNC mRNA, alongside their mirSVR score. The more negative the score, the greater the predicted 
effect on mRNA. Lines represent complementary base pairing, while the grey shading depicts the 
seed sequence of the miRNAs shown. (D) qRT-PCR analysis of TNC expression in immortalized PDAC-
associated fibroblasts transfected with miR-212-3p mimics (30nM), miR-137 mimics (30nM) or off-
target mimics (30nM) for 48hours, plus untreated cells. Expression was normalized to GAPDH using 
off-target siRNA as control. Data are shown as mean ±SEM; n=2 independent experiments; P-value 
determined by paired t-test. (E) Western blot of TNC in resin-concentrated conditioned media and 
cell lysates from experiment shown in D. (F) Normalized luciferase activity of TNC 3’-UTR cloned into 
pGL3-Control vector containing either wild-type (WT) or mutant (MUT) binding sites of hsa-miR-137 
(Supplementary Figure 2G), after co-transfection with miR-137 mimics and off-target negative 
control in HeLa cells. Data are fold changes of Firefly pGL3-Control constructs/Renilla pRL-SV40 
vector activity ratio normalized to off-target control ±SEM; n=2 independent experiments; P-value 
determined by paired t-test. (G and H) qRT-PCR for TNC (G) and mir-137 (H) after incubation of 
PDAC-associated and normal activated (NA) fibroblasts with recombinant human TGFβ1 for 48 
hours. Expression levels were compared to control (DMEM) and normalized to GAPDH and RNU6-2 
respectively. Error bars depict mean ± SEM; n=3 independent experiments. P-value determined by t-
test assuming unequal variance. 
 








Supplementary Table 1. Patient characteristics of samples used for discovery and independent 
validation. 
1IQR= interquartile range 
 Discovery Set Independent set 
PDAC CP PAT NA PDAC CP NA 
n=6 n=5 n=5 n=5 n=9 n=3 n=1 
Diagnosis for NA  
Mucinous Cystic 
Neoplasm 
 1  0 
IPMN 1 0 
PDAC 1 0 
CP 0 0 
PAT 2 1 
Median age (IQR)1 73 
(71.25-
77) 
46 (35-
54) 
67 (65-
73) 
64 (64-
65) 
65 (61-73) 37 (34.5-
40) 
54 
Gender  
    Female 5 4 5 2 4 2 1 
    Male 1 1 0 3 5 1 0 
Stage  
    IIA 1 --- 0 1 1 --- 0 
    IIB 5 --- 1 0 8 --- 0 
    III 0 --- 4 2 0 --- 1 
Tumour differentiation  
    Well differentiated 0 0 0 0 0 0 0 
    Moderate 2 0 1 3 2 0 0 
    Poor 4 0 4 0 7 0 0 
Alcohol  
    Yes 3 2 2 4 4 0 0 
    No 3 0 2 1 5 2 0 
    Ex 0 3 1 0 0 1 1 
Smoking  
    Yes 0 3 1 0 2 2 1 
    No 6 1 4 2 5 1 0 
    Ex 0 1 0 3 1 0 0 
    Missing 0 0 0 0 1 0 0 
Diabetes  
    Yes 1 2 2 1 4 1 1 
    No 5 2 3 4 5 2 0 
    Missing 0 1 0 0 0 0 0 
BMI Median (IQR) 27.71 
(27.01-
29.25) 
27.44 
(27.22 – 
27.66) 
28.72 
(26.43-
29.98) 
26.86 
(25.27-
32.84) 
23.73 
(21.74-
25.82) 
25 
(23.95-
25.67) 
31.24 
CA19-9 Median (IQR) 675 
(398.25-
1356) 
10 (7-13) 36 (5.5-
65.75) 
7 (7-12) 406 (182-
767) 
9 (7.5-
32) 
--- 
Lymph node ratio 
Median (IQR) 
0.117 
(0.093-
0.166) 
--- 0.5 (0.5-
0.56) 
0 (0-
0.052) 
0.181 
(0.076-
0.235) 
--- 0.75 
Tumour size Median 
(IQR) 
30 (25-
40) 
--- 40 (25-
40) 
47.5 
(37.5-55) 
35 (28.75-
41.25) 
--- 40 
Supplementary Table 2. Top 4 upstream regulators (with their activation z-score) significantly 
enriched in PDAC vs PAT and PAT vs CP, as determined using IPA. 
 
 
 
Upstream 
Regulators PDAC vs CP PDAC vs  PAT PAT vs CP 
MAPK1 2 2.21 0.74 
TGFβ1 N/A 2.57 -1.19 
P38 MAPK N/A 2.21 -0.39 
HIF1A N/A 1.97 N/A 
Supplementary Table 3. Patient characteristics of UoL serum sample cohorts. 
1
Pancreatic ductal adenocarcinoma without obstructive jaundice 
2
Pancreatic ductal adenocarcinoma with obstructive jaundice 
3
Benign biliary obstruction 
4
Chronic pancreatitis 
5
Healthy control 
 Discovery cohort Validation cohort 
 
PDAC 
non-
obs
1
 
PDAC-
obs
2
 
BBO
3
 CP
4
 HC
5
 
PDAC 
non-
obs
1
 
PDAC-
obs
2
 
BBO
3
 CP
4
 HC
5
 
n 20 15 10 15 15 30 35 27 35 28 
Median age 
(range) 
66 
(39-
78) 
66 
(39-
78) 
65.5 
(24-
80) 
48 
(36-
78) 
35 
(23-
65) 
69 
(51-
83) 
65 
(45-
81) 
72 
(23-
86) 
54 
(24-
78) 
44 
(22-
77) 
Sex   
F 9 8 3 9 5 17 18 12 11 20 
M 11 7 7 6 10 13 17 15 24 8 
Supplementary Table 4. Patient characteristics of samples included on TMAs histologically 
stained for TNC. 
 
 
 
 
 
 
 
1
Pancreatic ductal adenocarcinoma 
2
Chronic pancreatitis 
 PDAC
1
 TMA #1 PDAC
1
 TMA #2 CP
2
 TMA 
n 41 48 47 
Median age 
(range) 
67 
(45-81) 
68 
(44-84) 
52 
(21-77) 
Sex  
F 21 23 25 
M 20 25 21 
Missing 0 0 1 
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Supplementary Material and Methods 
 
Immunocytochemistry  
Cells were seeded on coverslips and fixed in 10% formalin (Sigma), permeabilized using 0.5% Triton 
X-100 for 10min and blocked for endogenous peroxidases using 1% hydrogen peroxide in methanol. 
Cells were washed 3 times with TBS before the addition of blocking solution (TBS containing 10% 
goat serum and 1% bovine serum albumin) for 30min at room temperature after which primary 
antibodies: anti-aSMA (1:500, Abcam #ab7817), anti-vimentin (1:1000, Abcam #ab8978), anti-
desmin (1:500, Abcam #ab15200), anti-pan-cytokeratin (1:300, Abcam #ab9377) and anti-CD68 
(1:500, Santa Cruz #sc-9139) were diluted in blocking solution and added to the cells for overnight 
incubation at 4˚C. Cells were washed and incubated with either horseradish peroxidase (HRP)-
conjugated secondary goat-anti-rabbit (1:100, Dako #P0448) or goat-anti-mouse (1:200, Dako 
#P0447) for 30min at room temperature and washed. A matching isotype control was included in 
each staining experiment.  Color was developed using the DAB chromogen system (Dako) for 5 min. 
Cells were counterstained with Mayer’s hematoxylin (Sigma) for 5 minutes.  
 
RNA isolation  
Total RNA (containing small RNAs) was isolated using the high pure miRNA isolation kit (one-column 
protocol) (Qiagen) following the manufacturer’s instructions. Purified total RNA was cleaned from 
genomic DNA using the DNA-freeTM DNA removal kit (ThermoFisher Scientific) following the 
manufacturer’s instruction. The median RNA integrity number (RIN) for the discovery samples 
applied to the mRNA/miRNA array was 8.1 (IQR= 7.7-8.4) (Agilent 2100 Bioanalyser). Quality and 
quantity of total RNA was assessed by NanoDropTM 2000C (ThermoFisher Scientific).  
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Array Data Analysis  
Probe expression data for mRNA and miRNA was generated from CEL files using Robust Multi-Array 
Average (RMA) normalization in Partek Genomics Suite software. Data were analyzed in 
R/Bioconductor with appropriate Affymetrix annotation. 
 
Differential expression analysis 
After normalization, mRNA probe measurements corresponding to 70,524 Affymetrix probe sets 
were mapped to 25,195 HUGO gene symbols per array. Measurements from 36,353 miRNA probe 
sets (representing 208 different species) included 6,631 human probe sets per array. Measurements 
from all probe sets were used for effective normalization while human only probe sets were used for 
miRNA expression analysis.  
 
Differential expression analysis of both mRNA and miRNA was performed using the Biocondcutor 
package limma. A design matrix was constructed with CP, PDAC, PAT, NA, NF-HSM, NF-LSM, RNA 
labelling date, array scan date and culture time as factors. The first six factors were biological factors 
representing fibroblast cell lines (from diseased tissue, normal adjacent tissue and commercial 
sources). While RNA labelling and scan dates were included to remove the influence of batch 
processing, culture time was included as an ordinal factor indicating relative duration of cell culture 
prior to nucleic acid extraction (≤7 days in culture=1; 8 to 14 days in culture =2; ≥15 days in 
culture=3). A linear model was fitted using this design before contrasts were generated in a second 
linear model for inference of differential expression. Contrasts were generated to compare cell-wise 
comparisons PDAC vs. CP; PDAC vs. PAT; PDAC vs. NA; PDAC vs. NF-HSM; CP vs. NA; CP vs. NF-HSM; 
PAT vs. NF-HSM; PAT vs. NA; PAT vs. CP; NF-HSM vs. NF-LSM; NA vs. NF-LSM; NA vs. NF-HSM. A 
further disease-wise set of contrasts was generated by pooling all diseased fibroblasts (PDAC, CP and 
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PAT) and comparing this group to NA and NF, respectively. The nestedF multiple testing strategy 
from the decideTests function in limma with FDR cut off 5% was used to avoid the accumulation of 
probe-wise and contrast-wise false positives. Clustering of expression data was performed in Partek 
Genomics Suite. For heat maps, samples and probes were clustered by average linkage using 
Euclidean distance. 
 
Pathway analysis of differentially expressed genes 
Using Ingenuity Pathway Analysis (IPA) core analysis was performed for functional analysis of 
differentially enriched gene lists. Canonical pathways were considered statistically significant if the 
negative log likelihood enrichment score exceeded 1.3. IPA upstream regulator function was used to 
determine potential transcriptional regulators to explain the identified changes in gene expression 
between the different fibroblasts comparison groups. The activation z-score was used to predict 
activation or inhibition of canonical pathways and/or transcriptional regulators based on published 
findings curated in IPA.  
 
Gene expression omnibus deposition  
The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus and 
are accessible through GEO Series accession number GSE123378 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123378).  
 
Quantitative real-time PCR Analysis for mRNA and microRNA  
Total RNA obtained from fibroblasts was reverse transcribed to form cDNA using the QuantiTect RT 
Kit (Qiagen) for mRNA analysis or the miScript II RT kit (Qiagen) for microRNA analysis and amplified 
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with a ready-to-use hot start reaction mix for SYBR Green I-based qRT-PCR (Roche) using the 
LightCycler® 480 Instrument. The primer sequences from PPAP2B, SULF1, FABP4, IGFBP5, HHIP, 
TNFSF4, TNC, ACTA2, AXIN2, RPLP0 and GAPDH were obtained from Primerdesign Ltd and primer 
sequences from NPPB, TGF-β1, hsa-let-7e-5p, hsa-miR-132-3p and RNU6-2 were obtained from 
Qiagen. mRNA or microRNA levels of the target genes analyzed were normalized with the 
corresponding housekeeping RNA level in the same sample. All reactions were performed in 
triplicate. In addition, a cDNA-free negative control and a reverse transcriptase free control was 
included. The results were calculated using the 2ΔCt method.  
 
Amplification refractory mutation system (ARMS) for KRAS mutation  
The KRAS mutation status of 6 specific point mutations (G12R, G12S, G12C, G12D, G12V, G12A) was 
evaluated as previously described (40).  
 
Conditioned media concentration  
Conditioned media was collected and centrifuged at 800g (at 4˚C) for 7min and processed with 
StrataClean resin (Agilent) for concentration of proteins. Briefly, a ratio of 1:400 (resin:sample) was 
mixed and vortexed for 1min and centrifuged at 800g (4˚C) for 1min. Supernatant was removed and 
resin washed twice with 500µl of 50mM ammonium bicarbonate and resuspended in 80µl of this 
solution. Samples were aliquoted and stored in -80˚C until use.  
 
Protein Extraction  
Cells were washed twice with cold PBS before addition of RIPA buffer supplemented with 
cOmplete™, Mini, EDTA-free Protease Inhibitor Cocktail (Roche) for 5 min. Cells were harvested with 
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a cell scrapper and transferred to a microcentrifuge tube on ice for 15 min (vortexing the samples  3 
times for 1 min at full speed during incubation). Cell debris was removed by centrifugation at 14,000 
× g for 15 min at 4°C, proteins were then quantified using the Bicinchoninic acid assay (ThermoFisher 
Scientific).  
 
Immunoblotting of conditioned media and cell lysates.  
Conditioned media from fibroblasts was collected and proteins concentrated with StrataClean resin 
(Agilent). Equal volumes of resin were mixed with loading buffer and heated at 95°C for 15 min and 
separated using SDS-PAGE before transferal to a PVDF membrane that was subsequently blocked in 
5% BSA for 1 hour before overnight incubation at 4°C with a TNC antibody (Novus Biologicals, 
#NB110-68136) diluted 1:1000. A further incubation followed for 1 hour at room temperature, with 
secondary anti-mouse HRP-bound antibodies (Dako) diluted 1:3000 in 5% BSA.  
For cell lysates, equivalent amounts of protein (5μg for TNC and 10μg for TGF-β1) were mixed with 
loading buffer and heated at 95 °C for 15 min to be size fractioned using SDS-PAGE before transfer to 
a PVDF membrane. The membrane was blocked in a 1% milk - 3% BSA mix for 1 hour with an 
overnight incubation at 4°C with the same TNC antibody (1:5000 dilution) or TGF-β1 (Abcam, # 
ab92486; 1:500 dilution). A further incubation followed for 1 hour at room temperature, with 
secondary anti-mouse or anti-rabbit HRP-bound antibodies respectively (Dako) diluted 1:5000 in a 
1% Milk - 3% BSA mix. Monoclonal anti-β-actin antibody (Sigma, #A2228) was used to check for 
protein loading. Images were visualized using western ECL substrate (Bio Rad) in a ChemiDoc Touch 
Imaging System (Bio Rad).  
 
Luciferase reporter gene construct 
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A 66-bp oligonucleotide fragment from the 3’-unstranslated region (3’-UTR) of TNC (position 7437 to 
7502, NM_002160.3) containing the miR-137 binding sites were cloned into the XbaI site of the 
pGL3-Control firefly luciferase reporter vector (Promega). A mutant construct was also generated by 
mutating the seed region of the miR-137 binding sites. The constructs were then confirmed by 
sequencing. HeLa cells were co-transfected using Lipofectamine 2000 (Invitrogen) with 100ng of 
each reporter constructs containing either the targeting sequence of the TNC 3’-UTR or its mutant in 
addition to miR-137 mimics (50nM) and off-target-AllStars negative control (50nM) (Qiagen). The 
pRL-SV40 vector (promega) was also co-transfected using 10ng to act as a Renilla luciferase control. 
The luciferase activities were measured 48h after transfection using Dual-Luciferase reporter assay 
system (Promega) and a Varioskan Flash microplate reader (Thermo Scientific) according to 
manufacturer’s instructions.  
 
Normal activated and PDAC-associated fibroblast immortalization 
To prepare retrovirus, packaging Phoenix cells were seeded and transfected 24h later with pWZL-
Blast-Flag-HA-hTERT (Addgene) using calcium-phosphate-mediated transfection. Normal activated 
and PDAC-associated fibroblasts were infected with retroviruses produced in the packaging cells 
(24h after transfection) in the presence of 5μg/mL Polybrene (Millipore) and were selected with 
5μg/mL blasticidin (Thermofisher Scientific). An additional plate of non-infected cells were included 
as a control to ensure drug selection.  
 
Activated stroma index (ASI) quantification 
Cores from successive PDAC TMAs stained for α-SMA and collagen were matched and quantified 
using ImageJ version 1.5. Color deconvolution was performed to isolate brown α-SMA staining and 
blue collagen staining. Images were deconvoluted into three colors using the RGB color model. The 
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following thresholds were used for α-SMA: Color 1 R=0.6027735, G=0.644836, B=0.46994755; Color 
2 R=0.34126425, G=0.56168777, B=0.753688; Color 3 R=0.7212509, G=0.5183564, B=0.45946032. 
For collagen: Color 1 R=0.76523894, G=0.5705916, B=0.29805133; Color 2: R=0.5437807, 
G=0.6563658, B=0.52295935; Color 3 R=0.34454608, G=0.4935677, B=0.79854804. 
Deconvoluted images were converted to 8-bit binary greyscale images, using the ‘Triangle’ auto-
threshold algorithm, and scaled to enable quantification of stained area in μm2. The activated 
stroma index was calculated as α-SMA area (μm2) ÷ collagen area (μm2) and the mean calculated 
across cores for each patient. 
 
Immunohistochemistry and Masson’s trichrome staining 
Deparaffinization and antigen retrieval were performed using pH9 antigen retrieval buffer in a PT 
Link (Dako). Sections were washed in 0.1% TBS Tween® 20 and blocked for endogenous peroxidases 
using peroxidase blocking reagent (Dako) at room temperature for 10 minutes. After further washing 
sections were dried and incubated with tenascin C antibody (clone 4C8MS, Novus Biologicals) diluted 
1:200 or α-SMA (Abcam) diluted 1:50 in antibody diluent (Dako) for 1 hour at room temperature. 
Incubation with labelled polymer anti-mouse secondary antibody (Dako) followed for a further 1 
hour at room temperature prior to visualisation with DAB+ chromogen (Dako), before 
counterstaining with haematoxylin then dehydration and mounting. Masson’s trichrome staining for 
collagen was performed according to the manufacturer’s instructions (Sigma-Aldrich). All whole 
sections and TMAs were qualitatively reviewed by a specialized histopathologist (FC). 
 
RNA in situ hybridisation 
In situ hybridization was performed using a commercial assay platform with probes specific for TNC 
(RNAscope® Reagent Kit, Advanced Cell Diagnostics), according to the manufacturer’s instructions 
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using the ‘Standard’ pretreatment protocol. Each run was accompanied with sections probed for 
peptidylprolyl isomerase B (PPIB) and dihydrodipicolinate reductase (dapB), a bacterial enzyme, as 
positive and negative controls for mRNA expression, respectively. 
